Publications
Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleLythgoe MP, Mullish BH, Frampton AE, et al., 2022,
Polymorphic microbes: a new emerging hallmark of cancer
, Trends in Microbiology, Vol: 30, Pages: 1131-1134, ISSN: 0966-842X -
Journal articlePowles STR, Gallagher KI, Chong LWL, et al., 2022,
Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome
, BMC Gastroenterology, Vol: 22<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Urinary and faecal metabolic profiling have been extensively studied in gastrointestinal diseases as potential diagnostic markers, and to enhance our understanding of the intestinal microbiome in the pathogenesis these conditions. The impact of bowel cleansing on the microbiome has been investigated in several studies, but limited to just one study on the faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Aim</jats:title> <jats:p>To compare the effects of bowel cleansing on the composition of the faecal microbiome, and the urine and faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Urine and faecal samples were obtained from eleven patients undergoing colonoscopy at baseline, and then at day 3 and week 6 after colonoscopy. 16S rRNA gene sequencing was used to analyse changes in the microbiome, and metabonomic analysis was performed using proton nuclear magnetic resonance (<jats:sup>1</jats:sup>H NMR) spectroscopy.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Microbiomic analysis demonstrated a reduction in alpha diversity (Shannon index) between samples taken at baseline and three days following bowel cleansing (<jats:italic>p</jats:italic> = 0.002), and there was no significant difference between samples at baseline and six weeks post colonoscopy. Targeted and non-targeted analysis of urinary and faecal bacterial associated metabolites showed no significant impact following bowel cleansing.</jats:p> </jats:sec><jats:sec>
-
Journal articleMullish BH, Martinez-Gili L, Chekmeneva E, et al., 2022,
Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection.
, Aliment Pharmacol Ther, Vol: 56, Pages: 1556-1569BACKGROUND: Factors influencing recurrence risk in primary Clostridioides difficile infection (CDI) are poorly understood, and tools predicting recurrence are lacking. Perturbations in bile acids (BAs) contribute to CDI pathogenesis and may be relevant to primary disease prognosis. AIMS: To define stool BA dynamics in patients with primary CDI and to explore signatures predicting recurrence METHODS: Weekly stool samples were collected from patients with primary CDI from the last day of anti-CDI therapy until recurrence or, otherwise, through 8 weeks post-completion. Ultra-high performance liquid chromatography-mass spectrometry was used to profile BAs. Stool bile salt hydrolase (BSH) activity was measured to determine primary BA bacterial deconjugation capacity. Multivariate and univariate models were used to define differential BA trajectories in patients with recurrence versus those without, and to assess faecal BAs as predictive markers for recurrence. RESULTS: Twenty (36%) of 56 patients (median age: 57, 64% male) had recurrence; 80% of recurrences occurred within the first 9 days post-antibiotic treatment. Principal component analysis of stool BA profiles demonstrated clustering by recurrence status and post-treatment timepoint. Longitudinal faecal BA trajectories showed recovery of secondary BAs and their derivatives only in patients without recurrence. BSH activity increased over time only among non-relapsing patients (β = 0.056; likelihood ratio test p = 0.018). A joint longitudinal-survival model identified five stool BAs with area under the receiver operating characteristic curve >0.73 for predicting recurrence within 9 days post-CDI treatment. CONCLUSIONS: Gut BA metabolism dynamics differ in primary CDI patients between those developing recurrence and those who do not. Individual BAs show promise as potential novel biomarkers to predict CDI recurrence.
-
Conference paperLythgoe M, Mullish B, Frampton A, et al., 2022,
ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY
, Publisher: BMJ PUBLISHING GROUP, Pages: A659-A659 -
Conference paperRouty B, Lenehan J, Daisley B, et al., 2022,
614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
, SITC 37th Annual Meeting (SITC 2022) Abstracts, Publisher: BMJ Publishing Group Ltd, Pages: A646-A646 -
Journal articleIaniro G, Mullish BH, Iqbal TH, et al., 2022,
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel
, The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 979-980, ISSN: 2468-1253 -
Conference paperMullish BH, Paizs P, Alexander J, et al., 2022,
Intestinal microbiota transplant for recurrent Clostridioides difficile infection restores microbial arylsulfatases and sulfatide degradation: a novel mechanism of efficacy?
, UEG Week 2022, Pages: 823-823 -
Journal articleForlano R, Sivakumar M, Mullish BH, et al., 2022,
Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
, International Journal of Molecular Sciences, Vol: 23, Pages: 8307-8307<jats:p>Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.</jats:p>
-
Journal articleMullish BH, McDonald JAK, Marchesi JR, 2022,
Intestinal microbiota transplantation: do not forget the metabolites
, The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 594-594, ISSN: 2468-1253 -
Journal articleTarazi M, Jamel S, Mullish BH, et al., 2022,
Impact of gastrointestinal surgery upon the gut microbiome: A systematic review
, Surgery, Vol: 171, Pages: 1331-1340, ISSN: 0039-6060
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.